Thirty years of progress in peritoneal dialysis

Journal of Nephrology

Volumn 12, Issue SUPPL. 2, 1999, Pages

  Maiorca, Rosario ^a,b   Cancarini, Giovanni ^a,b  

^a UNIVERSITY OF BRESCIA   (Italy)

^b Division of Nephrology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; HUMAN; METHODOLOGY; MORTALITY; PERITONEAL DIALYSIS; REVIEW; SURVIVAL RATE;

HUMANS; PERITONEAL DIALYSIS; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; SURVIVAL RATE;

EID: 0033155099     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. TcnckholTJ, Schlechter H. A bacteriological safe peritoneal access device. Trans Am Soc Artif Intern Organs 1968; 14: 181-7.
2. Boen ST. Kinetics of peritoneal dialysis. Medicine 1981; 40: 24SS7.
3. Scribner BH, Babb AL. Evidence for toxins of "middle" molecular weight. Kidney Int 1975; 7 (suppl 2): S349-51.
4. Babb AL, Jobanscn PJ, Strand MJ, Tcnckhoff H, Scribner BH. Bidirectional permeability of the human peritoneum to middle molecule. Proc Eur Dial Transplant Assoc 1973; 10: 247-57.
5. Gcjyo F, Yamada T, Odani S et al. A new form of amyloid protein associated with chronic hcmodialysis was identified as B2microglobulin. Biochcm Biophys Res Commun 1985; 129: 701-6.
6. Saito A, Suzuki I, Chung TG, Okamoto T, I lotta T. Separation of an inhibitor of crythropoicsis in "middle molecules" from hcmodialysatc from patients with chronic renal failure. Clin Chem 1986; 32: 1938-41.
7. Ilorl WII, Haag-Weber M, Gcargopoulos A, Block LH. Physicochemical characterization of a polypeptide present in urcmic scrum that inhibits the biological activity of polymorphonuclear cells. Proc Natl Acad Sei USA 1990; 87: 6353-7.
8. Haag-Weber M Hörl WH. Uremia and infection: mechanism of impaired cellular defense. Nephron 1993; 63: 125-31.
9. Attman PO, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993; 21: 573-92.
10. Seres DS, Strain GW, Hashim SA, Goldberg IJ, Levin NW. Improvement of plasma lipoprotein profiles during high-flux dialysis.J Am Soc Nephrol 1993; 3: 1409-15.
11. Cheung AK, Parker CJ, Ren K, Iverius PH. Increased lipase inhibitors in uremia: identification of pre-β-HDL as a major inhibitor in normal and uremie plasma. Kidney Int 1996; 49: 1360-71.
12. Makita Z, Bucala R, Rayfield EJ, et al. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 1994; 343: 1519-22.
13. Anderstam B, Mamoun AH, Södersten P, Bergström J. Middle-sized molecule fraction isolated from urémie ultrafiltrate and normal urine inhibit digestive behavior in the rat. J Am Soc Nephrol 1996; 7: 2453-60.
14. Popovich RT, Moncrief JW, Decherd JF, Bomar JD. A simplified clinical technique for the evaluation of peritoneal dialysis mass transport (MT) parameters. Am Soc Artif Intern Organs (Abstract) 1976; 5: 64.
15. Popovich RP, Moncrief JW, Decherd JP, Bomar JB, Pyle WK. The definition of a novel portable/wearable equilibrium peritoneal dialysis technique. Am Soc Artif Intern Organs (Abstract) 1976; 5: 64.
16. Oreopoulos DG, Robson M, Izatt S, Clayton S, de Veber GA. A simple and safe technique for CAPD. Trans Am Soc Artif Intern Organs 1978; 24: 484-9.
17. Buoncristiani U, Cozzari M, Quintaliani G et al. Abatement of exogenous peritonitis risk using the Perugia CAPD system. Dial Transplant 1983; 12: 14-25.
18. Bazzato G, Coli U, Landini S, et al. Continuous Ambulatory Peritoneal Dialysis without wearing a bag: complete freedom of patient and significant reduction of peritonitis. Proc Eur Dial Transplant Assoc 1980; 17: 266-75.
19. Maiorca R, Cantaluppi A, Cancarini GC, et al. Prospective controlled trial of a Y-connector and disinfectant to prevent peritonitis in continuous ambulatory peritoneal dialysis. Lancet 1983; 2: 642-4.
20. Viglino G, Colombo A, Scalamogna A, et al. Prospective randomized study of two Y devices in continuous ambulatory peritoneal dialysis (CAPD) Périt Dial Int 1989; 9: 165-8.
21. Churchill DN, Taylor DW, Vas SI, et al. Peritonitis in continuous ambulatory peritoneal dialysis (CAPD): a multicenter randomised clinical trial comparing the y-connector disinfectant system to standard system. Perit Dial Int 1989; 9: 159-63.
22. Saldanha L, Weiler E, Gonick FK. Effect of continuous ambulatory peritoneal dialysis on blood pressure control. AmJ Kidney Dis 1993; 21: 184-8.
23. Timio M, Ronconi M, Lori G, Venanzi S, Pede S. Effetto differenziato deH'emodialisi e della dialisi peritoneale ambulatoriale continua (CAPD) sull'ipertrofia asimmetrica settale dei pazienti uremici. Giorn It Nefrol 1985; 4: 157-60.
24. Wizemann V, Timio M, Alpert M, Kramer W. Options in dialysis therapy: significance of cardiovascular findings. Kidney Int 1993; 43 (suppl 40): S85-91.
25. Gaggiotti M, Cancarini GC, Maiorca R. Cardioprotection in CAPD: a reality or myth? Cardionephrology 4, Editoriale Bios Cosenza, Italy 1997: 249-53.
26. Tzamaloukas A, Avasfhti P. Temporal profile of serum potassium concentration in non-diabetic and diabetic outpatients on chronic dialysis. AmJ Nephrol 1987; 7: 101-9.
27. RottembourgJ, Issad B, Gallego JL, et al. Evolution of residual renal function in patients undergoing maintenance hemodialysis or continuous ambulatory peritoneal dialysis. Proc Eur Dial Transplant Assoc 1982; 19: 397-409.
28. Cancarini GC, Brunosi G, Camerini C, Brasa S, Manili L, Maiorca R. Renal function recovery and maintenance of residual diuresis in CAPD and hcmodialysis. Perit Dial Bull 1986; 6: 77-9.
29. Lysaght MJ, Vonesh EF, Gotch F, et al. The influence of dialysis treatment modality on the decline of remaining renal function. Trans Am Soc Artif Intern Organs 1991; 37: 598-604.
30. Twardowski ZJ, Khanna R. Peritoneal dialysis access and exit site care. In: Gokal R, Nolph KD, eds. The Textbook of Peritoneal Dialysis. Kluwer Academic Publishers, Dordrecht, 1994; 271-314.
31. Bergstrom J, Lindholm B. Nutrition and adequacy of dialysis. How do hemodialysis and CAPD compare? Kidney Int 1993; 43(suppl40):S39-50.
32. Young GA, Kopple JD, Lindholm B, et al. Nutritional assessement of continuous ambulatory peritoneal dialysis patients: an international study. AmJ Kidney Dis 1991; 27: 462-71.
33. Cianciaruso B, Brunori G, Kopple JD, Traverso GB, et al. Cross-sectional comparison of malnutrition in Continuous Ambulatory Peritoneal Dialysis and Hemodialysis patients. AmJ Kidney Dis 1995; 26: 475-86.
34. Maiorca R, Brunori G, Zubani R, et al. Predictive value of dialysis adequacy and nutritional indices for mortality and morbidity n CAPD and HD patients. A longitudinal study. Nephrol Dial Transplant 1995; 10 (12): 2295-305.
35. Cianciaruso B, Brunori G, Traverso G, et al. Nutritional status in the elderly patient with uraemia. Nephrol Dial Transplant 1995; 10 S6: 65-8.
36. Tane D, Fein PA, Antignani A, Mittman N, Avram MM. The impact of CAPD treatment on lipid metabolism and cardiovascular' risk. Adv Peril Dial 1990; 6: 234-7.
37. Avram MM, Goldwasser P, Burrel DE, Antignani A, Fein PA, Mittman N. The uremie dislipidemia: a cross-sectional study. AmJ Kidney Dis 1992; 20: 324-35.
38. Kroenenberg F, Uterman G, Dieplinger H. Lipoprotein(a) in renal disease. AmJ Kidney Dis 1996; 27:1-25.
39. Lameire N, Van Biesen W, Vanholder R. Consequences of using glucose in peritoneal dialysis fluid. Semin Dial 1998; 11: 271-5.
40. Krediet RT. Long-term peritoneal dialysis impact of peritoneal membrane changes and newer solutions. Int J Artif Organs 1998; 21: 437-9.
41. Selgas R, Bajo MA, Jimenez C, Garcia-Rubiales MA, Del Peso G, Munoz MA, Sanchez C, Fdez-Reyes MJ, Alvaro F. For how long is peritoneal dialysis possible? Analysis of peritoneal function among long-term CAPD patients. Perit Dial Int 1995;15(suppl):S21.
42. Struijk DG, Krediet RT, Koomen GCM, Hock FJ, Boeschoten EW, Reijden HJ, Arisz L. Functional characteristics of the peritoneal membrane in long-term continuous ambulatory peritoneal dialysis. Nephron 1991; 59: 213-20.
43. DobbieJW. Ultrastructurc and pathology of the peritoneum in Peritoneal Dialysis. In: Gokal R, Nolph KD, eds. The textbook of peritoneal Dialysis. Kluwer Academic Publishers, Dordrecht, 1994: 17-44.
44. Heaton A, Ward MK, Kerr D, et al. Short-term studies on the use of glycerol as an osmotyic agent in continuous ambulatory peritoneal dialysis. Cli Sei 1984; 67: 121-30.
45. De Paepe M, Matthys E, Lameirc N et al. Experience with glycerol as the osmotic agent in diabetic and non-diabetic patients. In: Keen H, Legrain M, eds. Prevention and treatment of diabetic nephropathy. Lancaster, UK, MTP Press, 1983: 299-313.
46. Faller B. Amino acid-based peritoneal dialysis solutions. Kidney Int 1996; 50 (suppl): S81-5.
47. Faller B, Aparicio M, Larroumet N, et al. Clinical evaluation of an optimized 1.1% amino acid solution for peritoneal dialysis. Nephrol Dial Transplant 1995; 10: 1432-7.
48. Mistry CD, Mallick NP, Gokal R. The use of large molecular weight polymer as an osmotic agent in continuous ambulatory peritoneal dialysis. Proc Eur Dial Transplant Assoc 1985; 22: 415-20.
49. Feriani M, Biasioli S, Borin D, et al. Bicarbonate solutions for peritoneal dialysis: a reality. IntJ Artif Organs 1985; 8: 57-8.
50. Reaich D, Channon SM, Scrimgeour CM, et al. Ammonium chloride induced acidosis increases protein breakdown and amino acid oxidation in humans. Am J Physiol 1992; 263: E735-9.
51. Lindholm B, Bergström J. Nutritional requirements of peritoneal dialysis patients. In: Gokal R, Nolph KD, eds. The textbook of Peritoneal Dialysis. Dordrecht, Kluwer Academic Publishers, 1994: 443-72
52. Yatzidis H. A new stable bicarbonate dialysis solution for peritoneal dialysis: preliminary report. Perit Dial Int 1991; 11: 224-7.
53. Coles GA, Gokal R, Ogg C, Jani F, O'Donoghue DT, Cancarini GC, Maiorca R, Tranaeus A, Faict D, de Vos C. A randomized controlled trial of a bicarbonate - and a bicarbonate/lactate - containing dialysis solution in CAPD. Perit Dial Int 1997; 17:48-51.
54. Nakayawa D, Price C, Stinebraugh B, Suki W. Continuous q-clic peritoneal dialysis: a viable option in the treatment of chronic renal failure. Trans Am Soc Artif Intern Organs 1981; 27: 55-7.
55. Diaz-Buxo JA, Walker PJ, Farner CD. Continuous cyclic peritoneal dialysis-a preliminary report Artif Organs 1981; 5:157-62.
56. Twardowski ZJ, Nolph KDS, Klianna R, et al. Peritoneal equilibration test. Peril Dial Bull 1987; 7: 13847.
57. Verger C, Larpent T, Dumontet M. Prognostic value of peritoneal equilibration curves in CAPD patients. In: Maher JF, TiinchesterJF, eds. Frontiers in peritoneal dialysis. New York: Field, Rich and Assoc 1986: 88-93.
58. Gotch FA, Sargent JA. A mechanistic analysis of the National Cooperative Dialysis Study. Kidney Int 1985; 28: 526-34.
59. Churchill DN, Taylor DW, Keshaviah PR. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. J Am Soc Nephrol 1996; 7: 198-207.
60. NFK-DOQI Clinical practice guidelines for Peritoneal Dialysis Adequacy. New York, National Kidney Foundation, 1997.
61. Bloembergen WE, Port FK, Mauger EA, Wolfe RA. A comparison of mortality between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol 1995; 6: 177-83.
62. Fenton SSA, Schaubel DE, Desmeules M, Morrison HI, Mao Y, Copleston P, JefferyJR, Kjellstrand CM. Hemodialysis versus peritoneal dialysis: a comparison of adjusted mortality rates. Am J Kidney Dis 1997; 30: 334-42.
63. Maiorca R, Cancarihi GC, Zubani R, Camerini C, Manili L, Brunori G, Movilli E. CAPD viability: a long-term comparison with hemodialysis. Perit Dial Int 1996; 16: 276-87.
64. Maiorca R, Cancarini GC, Brunori G, Zubani R, Camerini C, Manili L, Movilli E. Comparison of long-term survival between hemodialysis and peritoneal dialysis. Adv Peril Dial 1996; 12: 79-88.